METHODS

Blood pressure and urine biochemical indices were recorded. Renal blood flow was evaluated by renal ultrasonography. Transmission electron microscopy (TEM) and HE staining were used to assess kidney and spleen morphology. Renal fibrosis was assessed using Masson staining. Serum levels of IL-6, IL-10, and IL-17A were measured using ELISAs. The density of ROR and Foxp3 in the spleen was observed by immunofluorescence staining. The levels of Th17 cells and Tregs in blood were detected via flow cytometry. Transcriptome sequencing was performed to screen the targets of BSHM granules in hypertensive kidneys.

RESULTS

BSHM granules decreased SBP by 21.2 mm·Hg and DBP by 8.8 mm·Hg in ageing SHRs ( < 0.05), decreased the levels of urine mALB, 2-Mg, and NAG ( < 0.01), and improved renal blood flow and arteriosclerosis. BSHM granules increased IL-10 expression ( < 0.05) while decreasing IL-6 ( < 0.01) and IL-17A ( < 0.05) levels. BSHM granules improved Foxp3 density and the number of Tregs ( < 0.01) and reduced RORt density and the number of Th17 cells ( < 0.01). Transcriptome sequencing identified 747 differentially expressed (DE) mRNAs in kidneys after BSHM treatment. GO analysis suggested that BSHM granules act through immunoregulation.

CONCLUSIONS

BSHM granules attenuated hypertensive renal damage in ageing SHRs, by significantly increasing Tregs and decreasing Th17 cells.